Poor response to Eculizumab in Caucasian Patients with Treatment Refractory Generalized Myasthenia Gravis: A case series
Eculizumab resistance
DOI:
https://doi.org/10.17161/rrnmf.v4i2.18489Keywords:
Myasthenia Gravis, Eculizumab, complement inhibitorAbstract
Background
Eculizumab, a C5 complement inhibitor, has been approved for management of patients with treatment refractory Acetylcholine receptor positive (AChR+) Generalized Myasthenia Gravis (gMG). Though majority of patients receiving eculizumab experience clinical improvement, a small number of patients may have poor response.
Objective
To report three cases of poor response to eculizumab in young caucasian patients with treatment refractory gMG.
Methods
Case Series
Results
All three patients were young, caucasian, thymectomized, females with MGFA class III, treatment refractory MG on multiple immunosuppressant medications. All three patients had initial worsening of MG- ADL score, 1 month post eculizumab, followed by an unchanged MG ADL and MGC score, 3 months after eculizumab therapy. No changes were noted in the number of acute exacerbations of MG, pre and post eculizumab therapy. All patients were eventually started on maintenance Plasma-exchange (PLEX) therapy, post eculizumab failure and had clinical improvement in MG-ADL and MGC scores and reduction in the number of acute exacerbations of disease.
Conclusion
The exact mechanism contributing to poor clinical response to eculizumab in gMG patients remains unclear. Further studies are warranted to undermine the underlying pathogenesis.
Metrics
Downloads
References
Juel VC, Massey JM. Myasthenia gravis. Orphanet J Rare Dis. 2007;2:44. doi: 10.1186/1750-1172-2-44.
Schneider-Gold C, Hagenacker T, Melzer N, Ruck T. Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord. 2019;12:1756286419832242. Doi: 10.1177/1756286419832242.
Howard JF, Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti- acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-86. Doi: 10.1016/S1474-4422(17) 30369-1
Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve. 2019; 60(1):14-24. doi: 10.1002/mus.26447
Howard JF, Jr., Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76-84. doi: 10.1002/mus.23839
US Food and Drug Administration, “Drugs@FDA: soliris (BLA 125166),” 2018, https://www.accessdata.fda.gov/scripts/ cder/daf/index.cfm?event=BasicSearch.process.
Alexion Pharmaceuticals,” Soliris (Eculizumab), Alexion Pharmaceuticals, Cheshire, CT, USA, 2018, https://www. accessdata.fda.gov/drugsatfda_docs/label/2018/ 125166s426lbl.pdf.
Katyal N, Narula N, Govindarajan R. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. J Neuromuscul Dis. 2021;8(2):287-294. doi: 10.3233/JND-200584. PMID: 33325394; PMCID: PMC8075396.
Nishimura J. [Genetic variants in C5 and poor response to eculizumab]. Rinsho Ketsueki. 2015 Jul;56(7):855-60. Japanese. doi: 10.11406/rinketsu.56.855. PMID: 26251149.
Saskia Langemeijer, Jun-Ichi Nishimura, Wynne Weston-Davies, Miles A Nunn, Yuzuru Kanakura, Ian J Mackie, Petra Muus; C5 Polymorphism in a Dutch Patient with Paroxysmal Nocturnal Hemoglobinuria (PNH) and No Asian Ancestry, Resistant to Eculizumab, but in Vitro Sensitive to Coversin. Blood 2015; 126 (23): 1209. Doi: https://doi.org/10.1182/blood.V126.23.1209.1209.
Hillmen P, Muus P, Szer J, Hill A, Höchsmann B, Kulasekararaj A, Risitano AM, Van Den Neste E, Liljeholm M, Ebrahim KS, Bedrosian CL, Gao X, Ames D, Socié G. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2016 Mar;91(3):E16-7. doi: 10.1002/ajh.24280. PMID: 26690023.
Koren E, Zuckerman LA, Mire-Sluis AR. Immune responses to therapeutic proteins in humans–clinical significance, assessment and prediction. Curr Pharm Biotechnol 2002; 3: 349– 360.
Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36: 3– 10.
Nechansky A. HAHA―nothing to laugh about. Measuring the immunogenicity (human anti-human antibody response) induced by humanized monoclonal antibodies applying ELISA and SPR technology. J Pharm Biomed Anal 2010; 51: 252– 254.
Albazli K, Kaminski HJ, Howard JF Jr. Complement Inhibitor Therapy for Myasthenia Gravis. Front Immunol. 2020;11:917. Published 2020 Jun 3. doi:10.3389/fimmu.2020.00917
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Nakul Katyal MD, Raghav Govindarajan MD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
